The Genivent team has been investing in alternatives for decades and is opportunistically targeting accretive secondary transactions and GP equity positions. Genivent has an unconstrained mandate and acts as a dedicated liquidity sleeve for Omnigence Partner funds.

The team has been investing in farmland since 2007 and lower market private equity since 2013. We know the assets, values, operations and prospects of the Omnigence partner funds intimately, reducing information asymmetry risk that is common in secondary markets.
Genivent is typically able to transact secondaries at material discounts to par/NAV and has dedicated access to a large, ongoing pool of LP investors in the partner funds.
Unique uncorrelated return profiles via GP stakes, gross up from underlying return profiles, higher underlying asset liquidity, shorter portfolio to duration than primary investment.
We access the real-time reporting and monitoring systems of the underlying funds to rapidly and accurately monitor and deliver the information about Genivent’s holdings.
Secondary discounts, embedded gain in GP stake value, short implied portfolio duration, high run rate distributions combine to mitigate risk.
Genivent Partners is Omnigence's multi-asset alternative investment strategy, launched in 2025. It is an evergreen, unconstrained vehicle that invests in Omnigence's partner funds rather than directly in assets: it acquires LP secondary positions in those funds and holds GP stakes in Veripath Partners and Arvore Partners, acting as a dedicated liquidity sleeve for partner-fund investors.
An unconstrained multi-asset strategy has flexibility to invest across different asset classes without fixed allocation requirements. This allows the portfolio manager to allocate capital to the most attractive opportunities regardless of asset class, adjust weightings based on market conditions and valuations, access a broader range of return sources, and potentially reduce risk through dynamic diversification. Genivent uses its unconstrained mandate to invest across Omnigence's partner funds, through LP secondaries and GP stakes, rather than allocating directly to underlying assets.
Genivent Partners gains exposure to farmland and lower middle market private equity (PE) through Omnigence's partner funds: LP secondary positions in those funds, and GP stakes in Veripath Partners (farmland) and Arvore Partners (PE). The fund leverages Omnigence's expertise and proprietary technology platforms across all investments.
Multi-asset alternative strategies offer several benefits: diversification across multiple alternative asset classes in a single vehicle, flexibility to capitalize on relative value opportunities, professional asset allocation and rebalancing, reduced correlation to traditional stock and bond markets, potential for more consistent returns across market cycles, and access to institutional-quality alternatives through one investment.
While Veripath Partners focuses exclusively on farmland and Arvore Partners focuses on lower middle market private equity (PE), Genivent Partners invests in those funds rather than alongside them. It acquires LP secondary positions in the Omnigence partner funds — typically at material discounts to par/NAV — and holds GP stakes in Veripath and Arvore. This gives investors diversified exposure to Omnigence's strategies with high monthly distributions, a shorter implied portfolio duration than a primary fund commitment, and a dedicated liquidity route for intra-hold period liquidity needs.
An evergreen fund structure is open-ended, meaning it does not have a fixed end date like traditional closed-end private equity funds. Evergreen funds can accept new capital and provide liquidity on a periodic basis, offer longer investment horizons without forced selling, continuously recycle capital into new opportunities, and provide more flexibility for both the manager and investors.
Yes. Genivent Partners opportunistically acquires secondary positions in Omnigence partner funds, covering both lower middle market private equity (PE) and farmland. Because it has dedicated access to a large, ongoing pool of LP investors in those funds, Genivent is typically able to transact secondaries at material discounts to par/NAV. The team knows the assets, valuations, operations and prospects of the underlying funds intimately, which reduces the information asymmetry risk common in secondary markets.
A GP stake is an equity interest in the general partner (the management company) of a fund, which entitles the holder to a share of that manager's economics as its assets under management grow. Genivent Partners holds GP stakes in Veripath Partners, Omnigence's farmland strategy, and Arvore Partners, its lower middle market private equity (PE) strategy. These stakes provide unique uncorrelated returns driven by farmland appreciation and fund AUM growth.
Genivent Partners provides high monthly yield and exposure to AUM growth in Omnigence's farmland and private equity (PE) strategies. Distributions are supported by the high run rate distributions of the underlying secondary positions, the discounts at which those positions are acquired, and the embedded gain in GP stake value. The short implied portfolio duration relative to primary fund investments also shortens the time to realization.